OR WAIT 15 SECS
August 20, 2015.
The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, says business intelligence provider GBI Research. The company’s new report states that this increase, which will occur across the eight major markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada, will be driven primarily by rising multiple myeloma prevalence as a result of an aging population. Additionally, approvals during the forecast period for drugs that will supplement current market leaders, such as Revlimid, and offer improved therapeutic options, mainly in the relapsed/refractory setting, will also boost the market. Promising examples include ixazomib, ARRY-520 (filanesib), elotuzumab and daratumumab. However, Yasser Mushtaq, Senior Analyst for GBI Research, explains that various market barriers, such as a limited target patient population, will restrict any further growth in the multiple myeloma therapeutics arena by 2021. For more, see the GBI Research report Multiple Myeloma Therapeutics in Major Developed Markets to 2021